Xiaoyan Liu1,2, Marta Fiocco3, Jesse J Swen1, Henk-Jan Guchelaar1. 1. a Department of Clinical Pharmacy and Toxicology , Leiden University Medical Center , Leiden , The Netherlands. 2. b Institute of Clinical Pharmacology , Qilu Hospital of Shandong University , Jinan , China. 3. c Department of Medical Statistics and Bioinformatics , Leiden University Medical Center , Leiden , The Netherlands.
Abstract
BACKGROUND: An increasing number of studies have reported ethnic differences in sunitinib outcome in metastatic renal cell carcinoma (mRCC) patients. However, a comprehensive analysis is still lacking. Therefore, we systematically collected available published data and performed a meta-analysis to compare sunitinib efficacy and toxicity in Asian and Caucasian mRCC patients. METHODS: Data were extracted from published results from clinical trials, expanded access program and real-world clinical practice. Progression-free survival (or time to tumor progression), overall survival, objective response rate and adverse events were used as endpoints to evaluate the differences of sunitinib outcome between the two ethnicities. For adverse events, we focused the following clinically relevant side effects: diarrhea, fatigue, mucositis/stomatitis, hand-foot syndrome, hypertension, leukopenia, neutropenia and thrombocytopenia. RESULTS: A total of 33 publications including 9977 patients were available for meta-analysis. The efficacy of sunitinib in Asian patients was similar to that in Caucasian patients. However, Asian patients showed a higher incidence of all grades toxicity of hand-foot syndrome, > grade 2 fatigue, > grade 2 hand-foot syndrome and > grade 2 thrombocytopenia. CONCLUSION: Ethnic differences in adverse events of sunitinib in mRCC patients existed and dose adjustment in Asian patients may be considered.
BACKGROUND: An increasing number of studies have reported ethnic differences in sunitinib outcome in metastatic renal cell carcinoma (mRCC) patients. However, a comprehensive analysis is still lacking. Therefore, we systematically collected available published data and performed a meta-analysis to compare sunitinib efficacy and toxicity in Asian and Caucasian mRCC patients. METHODS: Data were extracted from published results from clinical trials, expanded access program and real-world clinical practice. Progression-free survival (or time to tumor progression), overall survival, objective response rate and adverse events were used as endpoints to evaluate the differences of sunitinib outcome between the two ethnicities. For adverse events, we focused the following clinically relevant side effects: diarrhea, fatigue, mucositis/stomatitis, hand-foot syndrome, hypertension, leukopenia, neutropenia and thrombocytopenia. RESULTS: A total of 33 publications including 9977 patients were available for meta-analysis. The efficacy of sunitinib in Asian patients was similar to that in Caucasian patients. However, Asian patients showed a higher incidence of all grades toxicity of hand-foot syndrome, > grade 2 fatigue, > grade 2 hand-foot syndrome and > grade 2 thrombocytopenia. CONCLUSION: Ethnic differences in adverse events of sunitinib in mRCC patients existed and dose adjustment in Asian patients may be considered.
Authors: Margarite D Matossian; Alexandra A Giardina; Maryl K Wright; Steven Elliott; Michelle M Loch; Khoa Nguyen; Arnold H Zea; Frank H Lau; Krzysztof Moroz; Adam I Riker; Steven D Jones; Elizabeth C Martin; Bruce A Bunnell; Lucio Miele; Bridgette M Collins-Burow; Matthew E Burow Journal: Womens Health Rep (New Rochelle) Date: 2020-09-24
Authors: Caitlin C Murphy; Hannah M Fullington; David E Gerber; Isaac Alex Bowman; Maneka Puligandla; Janice P Dutcher; Robert S DiPaola; Naomi B Haas Journal: Cancer Med Date: 2021-08-18 Impact factor: 4.452
Authors: Manuela Schmidinger; Robert J Motzer; Frederic Rolland; Michael Staehler; Michael Rink; Margitta Retz; Tibor Csoszi; John A McCaffrey; Ugo De Giorgi; Claudia Caserta; Ignacio Duran; Fawzi Benzaghou; Douglas O Clary; Laurence Albiges; Toni K Choueiri; Nizar M Tannir Journal: Acta Oncol Date: 2021-11-04 Impact factor: 4.311